Oracle: I Wouldn't Rush In To Buy

Despite the potential from a reported $300B OpenAI deal, Oracle's associated revenue impact is not expected until 2027, and near-term growth is constrained by modest FY26 CapEx ($35B) and OCI capacity limitations, even with OCI projected to grow 77% to $18B in FY26. The stock currently trades at a premium P/E compared to other hyperscalers, leading the analyst to advise against initiating a long position at current price levels.

Analysis

Oracle's long-term growth narrative, buoyed by a reported $300 billion OpenAI deal, is tempered by significant near-term headwinds. The financial benefits from this major deal are not anticipated to materialize on the income statement until 2027, creating a disconnect between current valuation and near-term earnings power. Despite management guiding for strong FY26 revenue growth of 16% and a 77% expansion in Oracle Cloud Infrastructure (OCI) to $18 billion, the analysis points to a modest FY26 CapEx of $35 billion as a key bottleneck. This capital constraint is expected to create OCI capacity limitations, capping the stock's immediate upside potential. Compounding these operational concerns is the stock's valuation, which trades at a premium P/E multiple when compared to the four largest hyperscalers, suggesting the current price may already reflect future growth that is still subject to execution risk.

Key Decisions for Investors

• Investors should be cautious of Oracle's premium P/E valuation relative to its hyperscaler peers, as it suggests an unfavorable risk/reward profile for initiating new long positions at current levels.
• Monitor the company's ability to scale its OCI capacity, as the modest $35B FY26 CapEx may hinder its ability to achieve the guided 77% OCI growth and meet ambitious multi-year targets.
• Consider the delayed revenue impact from the OpenAI partnership, as the lack of contribution until 2027 presents a near-term valuation risk that may not be suitable for investors with shorter time horizons.